Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: BriaCell Therapeutics Corp (BCTX)

BriaCell Therapeutics Corp. (BCTX) - corporate logo

BriaCell Therapeutics (BCTX) develops personalized methods for combating breast tumors, demonstrating resilience to economic downturns and an absence of seasonality. This price chart, with an EV/EBITDA metric at 0.00, links stable demand for treatment with a rigorous confrontation against global oncology behemoths. Meanwhile, intensive expenditures on final-stage testing place a significant strain on the company's financial stability.

BCTX BriaCell Therapeutics Corp.: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/12/2026

briacell.com - analytical breakdowns and key metrics (BCTX)

- stock price and consensus target price:
Stock Quotes BriaCell Therapeutics Corp|BCTX - Consensus Target
- company stock exchange capitalization indicators:
Market Value BriaCell Corp|BCTX - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share BriaCell|BCTX - Company Net Assets|Market Capitalization to Book Value Ratio briacell.com|BCTX - Company Assets
- debt and liquidity data:
Debt to Equity BriaCell Therapeutics|BCTX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital BriaCell|BCTX - Company Debts|Debt to Book Capitalization Ratio BriaCell Corp|BCTX - Company Long-Term Loans and Borrowings|Company Short-Term Debts BriaCell|Quick Ratio briacell.com
- business earnings and investment ratios data:
BCTX - Net Profit|Projected Future Earnings BriaCell Therapeutics|BCTX - Price to Earnings Ratio|Forward P/E Multiple BriaCell Therapeutics|BCTX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BriaCell Corp|BCTX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months BriaCell|BCTX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months briacell.com|BCTX - Earnings per share increase in current year|Expected earnings per share growth for next year BriaCell Therapeutics
Summary company analytics:BCTX (BriaCell Therapeutics Corp)
Original product of briacell.com

This indicator compares the total enterprise value, including net debt, with operating profit before depreciation and amortization, allowing for an assessment of the asset's real value regardless of the financing structure. An analysis of the EV/EBITDA multiple trend reveals the capitalization efficiency of BriaCell Therapeutics (BCTX), whose clinical trial outsourcing model minimizes capital expenditures by passing production risks onto external vendors.

Key competitors

Merus Corp - Enterprise Value to EBITDA Ratio|IMMP - Enterprise Value to EBITDA Ratio|ANIX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA atossatherapeutics.com|contexttherapeutics.com (CNTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Mersana Therapeutics, Inc.|EPIX (ESSA Pharma, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA QT Imaging, Inc. QTI